Neoplasms Clinical Trials in Bethesda, Maryland
8 studies are recruiting for neoplasms in Bethesda, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o…
- Stage
- Phase 2
- Ages
- Any age
- Site
- Local Institution - 01114, Bethesda, Maryland
- Locations
- 222 in total
- Run by
- Celgene
-
Collection of Tissue Samples for Cancer Research
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …
- Stage
- Not phased
- Ages
- 0 and older
- Site
- National Institutes of Health Clinical Center, Bethesda, Maryland
- Locations
- 17 in total
- Run by
- National Cancer Institute (NCI)
-
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Background: - Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is…
- Stage
- Not phased
- Ages
- Any age
- Site
- National Cancer Institute - Shady Grove, Bethesda, Maryland
- Locations
- 2 in total
- Run by
- National Cancer Institute (NCI)
-
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the "instruction book" for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were "turned off." Researchers want to see if a new drug can turn the genes back on…
- Stage
- Phase 1
- Ages
- 18 to 120
- Site
- National Institutes of Health Clinical Center, Bethesda, Maryland
- Run by
- National Cancer Institute (NCI)
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Background: People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see i…
- Stage
- Phase 2
- Ages
- 18 to 120
- Site
- National Institutes of Health Clinical Center, Bethesda, Maryland
- Run by
- National Cancer Institute (NCI)
-
Sample Collection and Tracking for the Developmental Therapeutics Clinic
Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. R…
- Stage
- Not phased
- Ages
- 18 to 120
- Site
- National Institutes of Health Clinical Center, Bethesda, Maryland
- Run by
- National Cancer Institute (NCI)
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a ne…
- Stage
- Phase 1
- Ages
- 18 to 120
- Site
- National Institutes of Health Clinical Center, Bethesda, Maryland
- Run by
- National Cancer Institute (NCI)
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- National Institutes of Health, Bethesda, Maryland
- Locations
- 19 in total
- Run by
- Marengo Therapeutics, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.